Telesis Bio Inc (TBIO)

$3.8

-0.13

(-3.31%)▲

Market is closed - opens 7 PM, 11 Sep 2024

Performance

  • $3.78
    $3.98
    $3.80
    downward going graph

    0.53%

    Downside

    Day's Volatility :4.92%

    Upside

    4.42%

    downward going graph
  • $3.03
    $24.48
    $3.80
    downward going graph

    20.39%

    Downside

    52 Weeks Volatility :87.64%

    Upside

    84.48%

    downward going graph

Returns

PeriodTelesis Bio IncIndex (Russel 2000)
3 Months
26.4%
0.0%
6 Months
-60.0%
0.0%
1 Year
-82.98%
0.0%
3 Years
-99.43%
-20.6%

Highlights

Market Capitalization
7.2M
Book Value
- $11.59
Earnings Per Share (EPS)
-30.42
Wall Street Target Price
4.0
Profit Margin
-253.19%
Operating Margin TTM
-675.74%
Return On Assets TTM
-26.52%
Return On Equity TTM
-147.84%
Revenue TTM
19.6M
Revenue Per Share TTM
11.63
Quarterly Revenue Growth YOY
-77.9%
Gross Profit TTM
15.6M
EBITDA
-32.9M
Diluted Eps TTM
-30.42
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-24.95
EPS Estimate Next Year
-18.89
EPS Estimate Current Quarter
-4.03
EPS Estimate Next Quarter
-6.58

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Telesis Bio Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 5.26%

Current $3.80
Target $4.00

Company Financials

FY18Y/Y Change
Revenue
1.4M
-
Net Income
-97.4M
↑ 46.58%
Net Profit Margin
-6.9K%
-
FY19Y/Y Change
Revenue
4.8M
↑ 238.38%
Net Income
-8.3M
↓ 91.48%
Net Profit Margin
-172.78%
↑ 6686.02%
FY20Y/Y Change
Revenue
6.6M
↑ 36.86%
Net Income
-18.0M
↑ 116.94%
Net Profit Margin
-273.87%
↓ 101.09%
FY21Y/Y Change
Revenue
11.0M
↑ 67.93%
Net Income
-39.0M
↑ 116.31%
Net Profit Margin
-352.78%
↓ 78.91%
FY22Y/Y Change
Revenue
27.4M
↑ 148.44%
Net Income
-48.5M
↑ 24.42%
Net Profit Margin
-176.68%
↑ 176.1%
FY23Y/Y Change
Revenue
27.5M
↑ 0.27%
Net Income
-47.7M
↓ 1.54%
Net Profit Margin
-173.49%
↑ 3.19%
Q1 FY23Q/Q Change
Revenue
6.3M
↓ 33.3%
Net Income
-11.1M
↑ 36.73%
Net Profit Margin
-176.04%
↓ 90.16%
Q2 FY23Q/Q Change
Revenue
8.7M
↑ 36.99%
Net Income
-8.3M
↓ 25.47%
Net Profit Margin
-95.78%
↑ 80.26%
Q3 FY23Q/Q Change
Revenue
5.6M
↓ 35.69%
Net Income
-10.6M
↑ 28.29%
Net Profit Margin
-191.07%
↓ 95.29%
Q4 FY23Q/Q Change
Revenue
7.0M
↑ 25.4%
Net Income
-17.7M
↑ 66.37%
Net Profit Margin
-253.5%
↓ 62.43%
Q1 FY24Q/Q Change
Revenue
3.4M
↓ 50.7%
Net Income
-8.6M
↓ 51.17%
Net Profit Margin
-251.08%
↑ 2.42%
Q2 FY24Q/Q Change
Revenue
1.6M
↓ 54.94%
Net Income
-12.6M
↑ 45.71%
Net Profit Margin
-811.94%
↓ 560.86%
FY18Y/Y Change
Total Assets
287.7M
↑ 44.88%
Total Liabilities
162.4M
↓ 44.41%
FY19Y/Y Change
Total Assets
38.8M
↓ 86.52%
Total Liabilities
46.3M
↓ 71.5%
FY20Y/Y Change
Total Assets
26.9M
↓ 30.7%
Total Liabilities
52.3M
↑ 13.09%
FY21Y/Y Change
Total Assets
116.3M
↑ 332.78%
Total Liabilities
25.5M
↓ 51.31%
FY22Y/Y Change
Total Assets
81.4M
↓ 30.02%
Total Liabilities
34.8M
↑ 36.6%
FY23Y/Y Change
Total Assets
70.4M
↓ 13.46%
Total Liabilities
40.9M
↑ 17.46%
Q1 FY23Q/Q Change
Total Assets
89.2M
↑ 9.59%
Total Liabilities
52.5M
↑ 51.0%
Q2 FY23Q/Q Change
Total Assets
114.5M
↑ 28.45%
Total Liabilities
86.6M
↑ 64.84%
Q3 FY23Q/Q Change
Total Assets
105.0M
↓ 8.29%
Total Liabilities
58.5M
↓ 32.41%
Q4 FY23Q/Q Change
Total Assets
70.4M
↓ 32.96%
Total Liabilities
40.9M
↓ 30.18%
Q1 FY24Q/Q Change
Total Assets
63.3M
↓ 10.06%
Total Liabilities
41.7M
↑ 1.98%
Q2 FY24Q/Q Change
Total Assets
52.7M
↓ 16.74%
Total Liabilities
42.8M
↑ 2.64%
FY19Y/Y Change
Operating Cash Flow
-6.4M
↓ 71.13%
Investing Cash Flow
-94.8K
-
Financing Cash Flow
35.1M
↓ 69.1%
FY20Y/Y Change
Operating Cash Flow
-15.4M
↑ 140.7%
Investing Cash Flow
-204.0K
↑ 115.19%
Financing Cash Flow
-96.0K
↓ 100.27%
FY21Y/Y Change
Operating Cash Flow
-36.7M
↑ 138.59%
Investing Cash Flow
-15.0M
↑ 7272.55%
Financing Cash Flow
121.1M
↓ 126226.04%
Q1 FY23Q/Q Change
Operating Cash Flow
-11.2M
↑ 98.03%
Investing Cash Flow
6.8M
↑ 0.0%
Financing Cash Flow
-18.0K
↓ 116.67%
Q2 FY23Q/Q Change
Operating Cash Flow
-10.3M
↓ 7.76%
Investing Cash Flow
6.8M
↑ 0.0%
Financing Cash Flow
26.7M
↓ 148461.11%

Technicals Summary

Sell

Neutral

Buy

Telesis Bio Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Telesis Bio Inc
Telesis Bio Inc
15.71%
-60.0%
-82.98%
-99.43%
-97.83%
Stryker Corporation
Stryker Corporation
10.37%
0.94%
19.75%
31.06%
67.96%
Boston Scientific Corp.
Boston Scientific Corp.
7.45%
23.41%
49.56%
83.54%
97.58%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
1.94%
-26.45%
-10.77%
-44.73%
-8.17%
Abbott Laboratories
Abbott Laboratories
5.62%
-5.27%
11.14%
-11.6%
36.83%
Medtronic Plc
Medtronic Plc
10.72%
5.13%
10.43%
-31.45%
-16.37%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Telesis Bio Inc
Telesis Bio Inc
70.62
NA
NA
-24.95
-1.48
-0.27
NA
-11.59
Stryker Corporation
Stryker Corporation
39.84
39.84
2.64
12.0
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
66.34
66.34
2.01
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
26.3
26.3
3.2
2.69
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
35.92
35.92
4.16
4.66
0.14
0.06
0.02
22.6
Medtronic Plc
Medtronic Plc
30.16
30.16
1.66
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Telesis Bio Inc
Telesis Bio Inc
Buy
$7.2M
-97.83%
70.62
-253.19%
Stryker Corporation
Stryker Corporation
Buy
$136.8B
67.96%
39.84
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$120.2B
97.58%
66.34
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$40.2B
-8.17%
26.3
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$198.1B
36.83%
35.92
13.65%
Medtronic Plc
Medtronic Plc
Buy
$115.3B
-16.37%
30.16
12.06%

Insights on Telesis Bio Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 6.97M → 1.55M (in $), with an average decrease of 52.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -8.63M → -12.58M (in $), with an average decrease of 45.7% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 51.5% return, outperforming this stock by 134.2%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 83.5% return, outperforming this stock by 182.9%

Institutional Holdings

    Company Information

    sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation.

    Organization
    Telesis Bio Inc
    Employees
    101
    CEO
    Mr. Eric Esser
    Industry
    Health Technology

    Discover More

    FAQs